Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.51 |
| ▸ | RAB9A | P51151 | 4/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.49 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.49 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.49 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MAOA | P21397 | 2/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17803570 | 0.93 | L3MBTL1 (0.48) | NPC1RAB9AL3MBTL1SMN1; SMN2KCNQ3 | |
| SCHEMBL17803523 | 0.90 | LMNA (0.48) | NPC1RAB9AL3MBTL1SMN1; SMN2KCNQ3 | |
| SCHEMBL17803603 | 0.90 | L3MBTL1 (0.47) | NPC1RAB9AL3MBTL1SMN1; SMN2KCNQ3 | |
| SCHEMBL17803512 | 0.89 | NPC1 (0.53) | NPC1RAB9AL3MBTL1SMN1; SMN2KCNQ3 | |
| SCHEMBL17803533 | 0.89 | SMN1; SMN2 (0.47) | NPC1RAB9AL3MBTL1SMN1; SMN2KCNQ3 | |
| SCHEMBL17803598 | 0.89 | L3MBTL1 (0.47) | NPC1RAB9AL3MBTL1SMN1; SMN2KCNQ3 | |
| SCHEMBL17803597 | 0.89 | L3MBTL1 (0.48) | NPC1RAB9AL3MBTL1SMN1; SMN2KCNQ3 | |
| SCHEMBL17803476 | 0.88 | MEN1 (0.48) | NPC1RAB9AL3MBTL1SMN1; SMN2KCNQ3 | |
| SCHEMBL17803506 | 0.88 | SMN1; SMN2 (0.47) | NPC1RAB9AL3MBTL1SMN1; SMN2KCNQ3 | |
| SCHEMBL17803483 | 0.88 | KCNQ3 (0.51) | NPC1RAB9AL3MBTL1KCNQ3KCNQ2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3227262-B1 | SULFIDE ALKYL AND PYRIDYL REVERSE SULFONAMIDE COMPOUNDS FOR HBV TREATMENT | NOVIRA THERAPEUTICS INC (US) | 2020-05-13 | — | — | EP | disclosed |
| US-10428041-B2 | Pyridyl reverse sulfonamides for HBV treatment | NOVIRA THERAPEUTICS, INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-20190152940-A1 | Pyridyl Reverse Sulfonamides For HBV Treatment | NOVIRA THERAPEUTICS, INC. | 2019-05-23 | — | — | US | disclosed |
| US-20180051000-A1 | Pyridyl Reverse Sulfonamides For HBV Treatment | NOVIRA THERAPEUTICS, INC. | 2018-02-22 | — | — | US | disclosed |
| US-20180051000-A1 | Pyridyl Reverse Sulfonamides For HBV Treatment | NOVIRA THERAPEUTICS, INC. | 2018-02-22 | — | — | US | disclosed |
| US-9765050-B2 | Pyridyl reverse sulfonamides for HBV treatment | NOVIRA THERAPEUTICS, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-9765050-B2 | Pyridyl reverse sulfonamides for HBV treatment | NOVIRA THERAPEUTICS, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-20160185748-A1 | PYRIDYL REVERSE SULFONAMIDES FOR HBV TREATMENT | NOVIRA THERAPEUTICS, INC. | 2016-06-30 | — | — | US | disclosed |
| US-20160185748-A1 | PYRIDYL REVERSE SULFONAMIDES FOR HBV TREATMENT | NOVIRA THERAPEUTICS, INC. | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190152940-A1 | Pyridyl Reverse Sulfonamides For HBV Treatment | HAVCR2, HCCS, NR1H4 | NPC1 798/4885RAB9A 2638/4885L3MBTL1 3492/4885 |
| US-10428041-B2 | Pyridyl reverse sulfonamides for HBV treatment | HAVCR2, HCCS, NR1H4 | NPC1 798/4885RAB9A 2638/4885L3MBTL1 3492/4885 |
| US-20180051000-A1 | Pyridyl Reverse Sulfonamides For HBV Treatment | HAVCR2, HCCS, NR1H4 | NPC1 798/4885RAB9A 2638/4885L3MBTL1 3492/4885 |
| US-20160185748-A1 | PYRIDYL REVERSE SULFONAMIDES FOR HBV TREATMENT | HAVCR2, HCCS, NR1H4 | NPC1 798/4885RAB9A 2638/4885L3MBTL1 3492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.